

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **FRONTAGE HOLDINGS CORPORATION**

**方達控股公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1521)**

### **CLOSING OF DISCLOSEABLE TRANSACTION ACQUISITION OF 100% EQUITY INTEREST IN QUINTARA DISCOVERY, INC.**

Reference is made to the announcement of Frontage Holdings Corporation (the “**Company**”) dated June 28, 2021 (the “**Announcement**”) in relation to the entering into of an Agreement and Plan of Merger (the “**Merger Agreement**”) by and among Frontage CA Merger Sub, Inc. (“**Merger Sub**”), a wholly-owned subsidiary of Frontage Laboratories, Inc., Quintara Discovery, Inc. (“**Target Company**”), the shareholders of Target Company and the shareholders’ representative, under which the parties agreed, among other things, to effect a reverse triangular merger in accordance with the California Corporation Code (the “**CCC**”). Unless otherwise specified, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that the transaction has closed and, as of July 9, 2021, the merger became effective. At the effective time of the merger, Merger Sub was merged with and into Target Company, whereupon the separate corporate existence of Merger Sub ceased and Target Company continued as the surviving entity and a wholly-owned subsidiary of Frontage Labs.

By Order of the Board  
**Frontage Holdings Corporation**  
**Dr. Song Li**  
*Chairman*

Hong Kong, July 29, 2021

*As at the date of this announcement, the Board comprises Dr. Song Li and Dr. Zhihe Li as executive directors; Mr. Jun Gao as non-executive director; and Mr. Yifan Li, Mr. Erh Fei Liu and Dr. Jingsong Wang as independent non-executive directors.*

\* *For identification purpose only*